返回 
加入收藏
基因多态性对含奥沙利铂化疗方案治疗Ⅲ、Ⅳ期结直肠癌疗效及毒副作用的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 基因多态性对含奥沙利铂化疗方案治疗Ⅲ、Ⅳ期结直肠癌疗效及毒副作用的影响 |
| TITLE： | Effects of gene polymorphism on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin treatment in stage Ⅲ and Ⅳ colorectal cancer |
| 摘要： | 目的 探讨GSTP1、XRCC1、ABCB1、MTHFR基因多态性对接受含奥沙利铂化疗方案Ⅲ、Ⅳ期结直肠癌患者疗效及毒副作用的影响。方法回顾性收集2018年9月至2020年3月苏州大学附属第二医院接受含奥沙利铂化疗方案（XELOX、FOLFOX）的Ⅲ、Ⅳ期结直肠癌患者资料76例。采用单因素、多因素COX回归模型分析基因型与无进展生存期（PFS）、毒副作用的相关性。结果ABCB13435T＞C位点C等位基因（TC/CC型）携带者的疾病进展风险显著高于TT基因型患者[HR＝2.39，95%CI（1.05，5.50），P＝0.038]，Ⅳ期患者的疾病进展风险显著高于Ⅲ期患者[HR＝8.11，95%CI（3.39，19.40），P＜0.001]；化疗方案、Karnofsky功能状态评分、肿瘤部位对疾病进展的影响不明显（P＞0.05）。基因位点的突变与不良反应无相关性（P＞0.05）。结论携带ABCB1TC/CC型且接受含奥沙利铂化疗方案患者的疾病进展风险较高，这可能与接受此类化疗方案的Ⅳ期结直肠癌患者（TT型）有更长的PFS相关，而GSTP1、XRCC1、MTHFR基因多态性无显著影响。 |
| ABSTRACT： | OBJECTIVE To investigate the effects of GSTP1， XRCC1， ABCB1， MTHFR gene polymorphisms on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin in patients with stage Ⅲ and Ⅳ colorectal cancer patients. METHODS Clinical data of 76 patients with stage Ⅲ and Ⅳ colorectal cancer who received chemotherapy regimen containing oxaliplatin （XELOX，FOLFOX） were collected from the Second Affiliated Hospital of Soochow University from September 2018 to March 2020. The correlation of genotypes with progression-free survival （PFS） and toxic effect was analyzed by using univariate and multivariate COX regression model. RESULTS Carriers of the ABCB1 3435T＞C locus C allele （TC/CC） had a significantly higher risk of progression compared to TT genotype patients [HR＝2.39， 95%CI （1.05，5.50）， P＝0.038]. The risk of progression in patients at stage Ⅳ was significantly higher than those at stage Ⅲ [HR＝8.11， 95%CI（3.39，19.40）， P＜0.001]. Chemotherapy regimen， Karnofsky performance status score and tumor site had no significant effect on disease progression （P＞0.05）. Mutations in gene loci were not correlated with adverse reactions （P＞0.05）. CONCLUSIONS Patients carrying ABCB1 TC/CC and receiving chemotherapy regimen containing oxaliplatin have a higher risk of disease progression， which may be associated with longer PFS in patients （TT genotype） with stage Ⅳ colorectal cancer receiving the chemotherapy， while GSTP1， XRCC1， and MTHFR gene polymorphisms have no significant impact. |
| 期刊： | 2024年第35卷第06期 |
| 作者： | 汤柳星；吕波；蒋文婷；项铮；沈珠；潘杰；苏存锦 |
| AUTHORS： | TANG Liuxing，LYU Bo，JIANG Wenting，XIANG Zheng，SHEN Zhu，PAN Jie，SU Cunjin |
| 关键字： | 奥沙利铂；基因多态性；结直肠癌；疗效；毒副作用；相关性 |
| KEYWORDS： | oxaliplatin； gene polymorphism； colorectal cancer； efficacy； toxic effect； correlation |
| 阅读数： | 8 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
